Delaware – January 2020, iQure Pharma Inc., a company dedicated to preclinical and early development of Oncology and Central Nervous System (CNS) compounds, announced today that their iQ-007 compound demonstrated an excellent safety and efficacy profile in tests performed by the NINDS ETSP, US. Results are in line with earlier findings and make iQ-007 an excellent candidate for Neuropathic Pain as lead indication and Epilepsy as secondary indication.
Novel, small molecule with an excellent Safety and Efficacy profile in Neuropathic Pain animal models. The compound exhibits the potential for a novel pain-relevant mode of action. One of the unique features of iQ-007 is its lack of sedation with an expanded spectrum of efficacy as an analgesic, anticonvulsant and anti-depressive agent. iQ-007 is currently entering pre-clinical development for painful Diabetic Peripheral Neuropathy as lead indication and Epilepsy as secondary indication.
About NINDS ETSP
The mission of the NINDS Epilepsy Therapy Screening Program (ETSP) is to encourage and facilitate the discovery of new therapeutic agents for the treatment of epilepsy disorders. These tests are performed at a contract facility based at the University of Utah on a blinded and confidential basis. Since its establishment in 1975, the program has made important contributions to the development of several FDA-approved drugs for epilepsy, including felbamate (Felbatol®), topirimate (Topamax®), lacosamide (Vimpat®), and retigabine (Potiga®).
Pawel Zolnierczyk, CEO
We are delighted to learn that ETSP’s experimental results in the area of Epilepsy confirmed iQ-007’s promising safety profile. ETSP is a prestigious organization, which, because it conducts its studies in a blinded setting, can be regarded as fully independent. Although we knew that iQ-007’s lead indication and promising profile was in Neuropathic Pain, learning that it has proven its potential to expand into the Epilepsy indication as well, is exciting news. We will continue to monitor the progress at ETSP closely and make sure we fully exploit iQ-007’s potential.